首頁 > 市場調查報告書 > 製藥

癌症

男性乳癌治療市場規模、佔有率及成長分析（按類型、產品類型、治療方法、診斷、最終用戶和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1907444

男性乳癌治療市場規模、佔有率及成長分析（按類型、產品類型、治療方法、診斷、最終用戶和地區分類）－2026-2033年產業預測

Male Breast Cancer Treatment Market Size, Share, and Growth Analysis, By Type, By Product Type, By Treatment, By Diagnosis, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月22日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球男性乳癌治療市場規模預計在 2024 年達到 45.6 億美元，從 2025 年的 47.3 億美元成長到 2033 年的 63.3 億美元，在預測期（2026-2033 年）內複合年成長率為 3.7%。

全球男性乳癌治療市場的特徵是這種癌症類型較為罕見，這主要是由於BRCA2基因突變等遺傳因素的影響。雖然男性乳癌會影響所有年齡層的男性，但在老年人族群中的發生率更高，而人口老化和肥胖率上升進一步加劇了這一趨勢。預計市場成長將歸因於癌症病例數量的增加、生物技術的進步以及創新治療方法的研發。意識提升和早期診斷的普及改善了存活率。然而，挑戰依然存在，例如缺乏統一的治療方案以及高昂的研發成本等問題阻礙了市場擴張。對於尋求新療法以應對這一複雜挑戰的製藥公司而言，該市場仍然是一個熱門研究領域。

全球男性乳癌治療市場促進因素

全球男性乳癌治療市場正受到公眾意識提升和早期檢測方法進步的顯著推動。公眾教育和宣傳活動在促進男性乳癌的及時診斷方面發揮了關鍵作用，從而提高了存活率和治療效果。隨著綜合篩檢項目和創新診斷技術的整合，早期發現與改善患者預後之間的關聯日益緊密。這些進步使醫療專業人員能夠更早啟動治療，最終造福患者健康，並再次強調了早期療育在疾病管理中的重要性。

限制全球男性乳癌治療市場的因素

由於男性乳癌的發生率遠低於女性乳癌，全球男性乳癌治療市場面臨嚴峻挑戰。這種罕見性導致針對男性患者的臨床試驗數量有限，研究也相對匱乏。因此，缺乏性別特異性研究阻礙了針對男性患者制定個人化治療通訊協定，可能導致男性患者接受的治療方案主要基於女性患者的研究成果。這種差異引發了人們對治療效果的擔憂，因為治療策略可能並未針對男性患者進行充分最佳化，最終影響患者的整體治療效果和醫療品質。

男性乳癌治療市場的全球趨勢

全球男性乳癌治療市場正經歷重大變革，這主要得益於人們對男性乳癌的認知和重視程度不斷提高。男性乳癌確診病例的不斷增加使其成為醫學界關注的焦點，促使人們增加對相關研究、創新治療方法和標靶治療的投入。這種轉變促使製藥公司和醫療機構加強合作，以改善針對男性的診斷通訊協定和治療選擇。隨著人們對男性乳癌的了解不斷加深，預計市場規模將進一步擴大，反映出各方為解決這一重要健康問題所做的更多努力。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Pfizer Inc.（USA）
Johnson & Johnson（USA）
Novartis AG（Switzerland）
Roche Holding AG（Switzerland）
GlaxoSmithKline plc（UK）
Sanofi SA（France）
Bayer AG（Germany）
Bristol-Myers Squibb Company（USA）
Eli Lilly and Company（USA）
AstraZeneca plc（UK）
Teva Pharmaceutical Industries Ltd.（Israel）
Sun Pharmaceutical Industries Ltd.（India）
BioNumerik Pharmaceuticals, Inc.（USA）
Seattle Genetics, Inc.（USA）
Accord Healthcare Ltd.（UK）
Merck & Co., Inc.（USA）
Fresenius SE & Co. KGaA（Germany）
Mylan NV（USA）
AbbVie Inc.（USA）
Amgen Inc.（USA）

結論與建議

簡介目錄

Product Code: SQMIG35D2234

Global Male Breast Cancer Treatment Market size was valued at USD 4.56 Billion in 2024 and is poised to grow from USD 4.73 Billion in 2025 to USD 6.33 Billion by 2033, growing at a CAGR of 3.7% during the forecast period (2026-2033).

The global male breast cancer treatment market is characterized by the rare occurrence of this cancer type, primarily influenced by genetic factors such as mutations in the BRCA2 gene. While it affects men of all ages, prevalence is higher among older demographics, exacerbated by aging populations and the increasing rates of obesity. Forecasted growth in the market is attributed to rising cancer cases and advancements in biotechnology, alongside the development of innovative therapies. Improved awareness and early diagnosis have enhanced survival rates. However, challenges persist, including the lack of a unified treatment approach and high research and development costs, which hinder market expansion. The market remains a focal area for pharmaceutical companies seeking to address these complexities through novel treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Male Breast Cancer Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Male Breast Cancer Treatment Market Segments Analysis

Global Male Breast Cancer Treatment Market is segmented by Type, Product Type, Treatment, Diagnosis, End User and region. Based on Type, the market is segmented into Ductal Carcinoma in Situ, Paget's Disease of the Nipple, Inflammatory Breast Cancer, Infiltrating Ductal carcinoma and Others. Based on Product Type, the market is segmented into Chemotherapy, Medication and Others. Based on Treatment, the market is segmented into Local Treatments, Radiation Therapy, Targeted Therapy and Systemic Treatments. Based on Diagnosis, the market is segmented into Mammography, Biopsy, Fine Needle Aspiration Biopsy, Core Biopsy, Excisional Biopsy, PET Scan, CT Scan, MRI Scan and Other Tests. Based on End User, the market is segmented into Hospitals, Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Male Breast Cancer Treatment Market

The global male breast cancer treatment market is significantly driven by heightened awareness and the advancement of early detection methods. Initiatives aimed at educating the public and promoting awareness have played a crucial role in facilitating the timely diagnosis of male breast cancer, leading to improved survival rates and treatment efficacy. Enhanced patient outcomes are increasingly linked to early detection, thanks to comprehensive screening programs and the integration of innovative diagnostic technologies. These developments enable healthcare professionals to initiate treatment at an earlier stage, ultimately benefiting patient health and reinforcing the importance of early intervention in managing this disease.

Restraints in the Global Male Breast Cancer Treatment Market

The Global Male Breast Cancer Treatment market faces significant challenges due to the relative rarity of the condition in comparison to female breast cancer. This scarcity results in a limited number of clinical trials and insufficient research focused on male patients. Consequently, the absence of gender-specific studies hampers the development of tailored treatment protocols, potentially leading men to receive care based on research primarily conducted on women. This discrepancy raises concerns regarding the effectiveness of treatments, as the therapeutic strategies may not be fully optimized for male patients, ultimately affecting their overall outcomes and quality of care.

Market Trends of the Global Male Breast Cancer Treatment Market

The Global Male Breast Cancer Treatment market is experiencing a significant transformation driven by heightened awareness and recognition of the disease among men, traditionally overshadowed in the broader oncology landscape. The increase in diagnosed male breast cancer cases has catalyzed a dedicated focus from the medical community, promoting investments in specialized research, innovative treatment modalities, and targeted therapies. This shift is fostering partnerships between pharmaceutical companies and healthcare institutions to enhance diagnostic protocols and treatment options tailored specifically for men. As elucidation of male breast cancer becomes more mainstream, the market is expected to expand, reflecting a growing commitment to addressing this critical health issue.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement

Global Male Breast Cancer Treatment Market Size by Type & CAGR (2026-2033)

Market Overview
Ductal Carcinoma in Situ
Paget's Disease of the Nipple
Inflammatory Breast Cancer
Infiltrating Ductal carcinoma
Others

Global Male Breast Cancer Treatment Market Size by Product Type & CAGR (2026-2033)

Market Overview
Chemotherapy
Medication
Others

Global Male Breast Cancer Treatment Market Size by Treatment & CAGR (2026-2033)

Market Overview
Local Treatments
Radiation Therapy
Targeted Therapy
Systemic Treatments

Global Male Breast Cancer Treatment Market Size by Diagnosis & CAGR (2026-2033)

Market Overview
Mammography
Biopsy
Fine Needle Aspiration Biopsy
Core Biopsy
Excisional Biopsy
PET Scan
CT Scan
MRI Scan
Other Tests

Global Male Breast Cancer Treatment Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Clinics
Others

Global Male Breast Cancer Treatment Market Size & CAGR (2026-2033)

North America (Type, Product Type, Treatment, Diagnosis, End User)
- US
- Canada
Europe (Type, Product Type, Treatment, Diagnosis, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Product Type, Treatment, Diagnosis, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Product Type, Treatment, Diagnosis, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Product Type, Treatment, Diagnosis, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNumerik Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seattle Genetics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Accord Healthcare Ltd. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius SE & Co. KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments